Hua Medicine-B (HKEX: 02552) announced that all seven resolutions tabled at its 25 June 2026 Annual General Meeting were approved by poll, confirming continued shareholder support for the company’s strategic and governance agenda.
Key Outcomes 1. Financial Statements and Reports • The 2025 audited consolidated financial statements and accompanying directors’ and auditors’ reports were unanimously accepted, with 100 % of the 13.29 million votes cast in favour.
2. Board Composition and Remuneration • Executive Director Dr. Yi Zhang was re-elected with 100 % support (13.29 million votes). • Non-executive Director Robert T. Nelsen received 68.85 % support (9.15 million votes), while 31.15 % voted against. • Independent Non-executive Director William R. Keller secured re-election with 91.47 % approval (12.16 million votes). • The Board was unanimously authorised to determine directors’ remuneration (100 % approval).
3. Auditor Re-Appointment • Deloitte Touche Tohmatsu was re-appointed as external auditor, with 68.85 % support (9.15 million votes).
4. Share Issuance and Repurchase Mandates • A 10 % share repurchase mandate obtained full shareholder backing (100 % approval). • Authorities to issue up to 20 % of issued shares and to extend this mandate by the number of shares repurchased were each approved by 68.85 % of votes.
5. Corporate Governance Update • A special resolution to adopt the fourth amended and restated Memorandum and Articles of Association passed with 82.04 % support (10.91 million votes), surpassing the 75 % threshold.
Participation and Voting Base • Total issued shares: 1.06 billion. • Shares eligible to vote: 1.06 billion. • Shares held under the company’s share schemes (57.98 million) abstained from voting in accordance with Hong Kong listing requirements. • All directors were present at the meeting; Tricor Investor Services acted as vote scrutineer.
Implications The decisive endorsement of every agenda item, particularly the governance amendments and refreshed capital mandates, provides the Board and management team—led by CEO and Executive Director Dr. Li Chen—with a clear mandate to pursue strategic and operational initiatives in the coming year.